We have shown previously that intranasal administration of encephalitogenic peptides in soluble form to H-2 u and H-2 s mice affords protection from experimental autoimmune encephalomyelitis (EAE). Here we demonstrate that this method of disease protection can be induced in C57BL/6 mice by administration of the soluble peptide 35-55 from myelin oligodendrocyte glycoprotein. This protective effect was demonstrated by the evaluation of both clinical EAE scores and central nervous system histopathology; the latter showing minimal inflammatory infiltrates in treated mice. The employment of an IL-10 −/− congenic strain allowed an appraisal of the involvement of IL-10 in this process. The lack of disease protection in these mice clearly demonstrates the non-redundant role of IL-10 in this process.
Introduction
Approximately 1 in 20 individuals in Europe and North America suffer from an autoimmune disease. Current treatments for serious autoimmune diseases are based on therapies that suppress the immune system non-specifically. Such therapies are potent and can have adverse consequences for the patient including; 1. Non-specific targeting of host defenses can result in an impaired ability to fight off infection. 2. Immunosuppression is required continuously until the disease is controlled. 3. Non-specific immunosuppression can hamper the natural induction of tolerance. 4. Life-long immunosuppression is expensive. In view of this, there is clearly the need to design more specific therapies. Attempts to focus therapy more specifically have been undertaken in diseases such as multiple sclerosis (MS). Thus, IFN-β, although initially tested as an anti-viral agent, has now been shown to have antiinflammatory effects that reduce relapse rate in relapsingremitting MS (Zhang et al., 2002) . Furthermore, glatiramer acetate, a random co-polymer of amino acids that mimics myelin basic protein, has been shown to induce a shift from Th1 to Th2 responses in vitro (Duda et al., 2000) and is now a frontline treatment for relapsing-remitting MS (Goodin et al., 2002) .
Recent studies in animals have investigated more antigenspecific therapies for autoimmune diseases (Wraith, 2004) . In particular, the use of peptides based on the sequences of known disease-associated antigens has been studied in both allergy and autoimmune disease (Larche and Wraith, 2005) . Many of these studies have employed experimental autoimmune encephalomyelitis (EAE) as an animal model for MS. Intranasal peptide deposition has been successfully used to prevent and treat EAE in both mouse and rat models (Anderton and Wraith, 1998; Metzler and Wraith, 1993; Xu et al., 2000) . Indeed peptide treatment has been shown to 
